Latest news

• FDA rejects GSK’s Nucala for COPD

  Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab). ... In May, AZ’s Fasenra failed a phase III trial in this indication as it was unable to show a benefit compared to placebo reducing exacerbations.

• AZ, Amgen’s first-in-class asthma drug gets breakthrough status

  Drugs like Fasenra and GlaxoSmithKline’s rival IL-5 inhibitor Nucala (mepolizumab) have emerged as an important treatment option for people with severe asthma characterised by high levels of eosinophils. ... Nucala made £245m ($317m) in the first six

• New cancer drugs can’t quite plug the revenue hole at AZ

  Fasenra (benralizumab) although overall respiratory sales were flat in the first half at $2.41bn. ... AZ’s decision to price IL-5 inhibitor Fasenra below rival products from GlaxoSmithKline and Teva seems to have helped get the drug moving quickly with

• Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

  Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use. ... News from pharma, biotech and healthcare. Limited NICE approval for AZ’s asthma drug Fasenra.

• PMCPA takes AZ to task over asthma drug press release

  that the claim in the press release was an advertisement for Fasenra, a prescription only medicine, to the public”. ... It also ruled that the statement about placebo-like AERs exaggerated the properties of Fasenra.